Jubilee Hills, India
Jubilee Hills, India

Time filter

Source Type

Price T.J.,University of Adelaide | Peeters M.,University of Antwerp | Kim T.W.,University of Ulsan | Li J.,Fudan University | And 7 more authors.
The Lancet Oncology | Year: 2014

Background: The anti-EGFR monoclonal antibodies panitumumab and cetuximab are effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. We assessed the efficacy and toxicity of panitumumab versus cetuximab in these patients. Methods: For this randomised, open-label, phase 3 head-to-head study, we enrolled patients (from centres in North America, South America, Europe, Asia, Africa, and Australia) aged 18 years or older with chemotherapy-refractory metastatic colorectal cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, and wild-type KRAS exon 2 status. Using a computer-generated randomisation sequence, we assigned patients (1:1; stratified by geographical region and ECOG performance status, with a permuted block method) to receive panitumumab (6 mg/kg once every 2 weeks) or cetuximab (initial dose 400 mg/m2; 250 mg/m2 once a week thereafter). The primary endpoint was overall survival assessed for non-inferiority (retention of ≥50% of the cetuximab treatment effect; historical hazard ratio [HR] for cetuximab plus best supportive care vs best supportive care alone of 0·55). The primary analysis included patients who received one or more dose of panitumumab or cetuximab, analysed per allocated treatment. Recruitment for this trial is closed. The trial is registered with ClinicalTrials.gov, number NCT01001377. Findings: Between Feb 2, 2010, and July 19, 2012, we enrolled and randomly allocated 1010 patients, 999 of whom began study treatment: 499 received panitumumab and 500 received cetuximab. For the primary analysis of overall survival, panitumumab was non-inferior to cetuximab (Z score -3·19; p=0·0007). Median overall survival was 10·4 months (95% CI 9·4-11·6) with panitumumab and 10·0 months (9·3-11·0) with cetuximab (HR 0·97; 95% CI 0·84-1·11). Panitumumab retained 105·7% (81·9-129·5) of the effect of cetuximab on overall survival seen in this study. The incidence of adverse events of any grade and grade 3-4 was similar across treatment groups. Grade 3-4 skin toxicity occurred in 62 (13%) patients given panitumumab and 48 (10%) patients given cetuximab. The occurrence of grade 3-4 infusion reactions was lower with panitumumab than with cetuximab (one [<0·5%] patient vs nine [2%] patients), and the occurrence of grade 3-4 hypomagnesaemia was higher in the panitumumab group (35 [7%] vs 13 [3%]). We recorded one treatment-related fatal adverse event: a lung infection in a patient given cetuximab. Interpretation: Our findings show that panitumumab is non-inferior to cetuximab and that these agents provide similar overall survival benefit in this population of patients. Both agents had toxicity profiles that were to be expected. In view of the consistency in efficacy and toxicity seen, small but meaningful differences in the rate of grade 3-4 infusion reactions and differences in dose scheduling can guide physician choice of anti-EGFR treatment. Funding: Amgen Inc. © 2014 Elsevier Ltd.


According to a new report published by Future Market Insights titled “Outbound Medical Tourism Services Market: North America Industry Analysis and Opportunity Assessment, 2016–2026”, the North America outbound medical tourism services market is expected to reach a market valuation of US$ 15.53 Bn by 2016 end and this is likely to increase to US$ 150.36 Bn by 2026. According to Future Market Insights, factors such as a large ageing baby boomer population, large uninsured population, and better technology and wider treatment options are expected to drive the revenue growth of the North America outbound medical tourism services market over the forecast period. Economic factors such as rising rate of health insurance premiums, high cost of medical treatments in the U.S., and parallel tourism with medical treatment are expected to boost the growth of the North America outbound medical tourism services market between 2016 and 2026. The other factors impacting the North America outbound medical tourism services market are long waiting time for specialist appointments in the U.S. and increasing preference for non-conventional treatment options. The demand for cosmetic correction procedures and dental treatments has been significantly high in the U.S. market in recent years, making North America the most lucrative regional market for outbound medical tourism services. According to the International Society of Aesthetic Plastic Surgery, the U.S. was the largest market for cosmetic procedures in 2015. Lack of effective follow-up care on returning home, rampant medical malpractices in medical tourism destinations, proliferation of superbugs in medical tourism destinations, problems associated with language barriers, and privacy concerns are some of the challenges anticipated to restrict revenue growth of the North America outbound medical tourism services market over the forecast period. The North America outbound medical tourism services market is segmented into the following therapeutic applications – Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment, and Other General Treatment. The North America outbound medical tourism services market is segmented into the two top countries of U.S and Canada. U.S. is projected to occupy a major share in the North America outbound medical tourism services market in terms of value. The U.S market is anticipated to be valued at US$ 14.98 Bn by the end of 2016. In terms of value, U.S. is expected to be the dominant regional market by 2026 end and is expected to register a CAGR of 25.7% over the forecast period. Canada is expected to have comparatively less market potential for outbound medical tourism services, registering a CAGR of 18.1% over the forecast period. The report profiles some of the top companies operating in the North America outbound medical tourism services market. Leading market players featured in the report are Apollo Hospital Enterprise Limited, Bumrungrad International Hospital, KPJ Healthcare Berhad, Christus Muguerza Hospital, WorldMed Assist, Mednamaste, and Global Medical Tourism Inc. Major market players are adopting strategies such as market expansion and strategic alliances to maintain their market share. Some of these companies are also adopting strategies such as backward integration to support their core business of medical tourism. Companies are offering services such as insurance and financing for medical tourism and are looking to expand their global footprint by enhancing their foreign customer base.


— According to a new report published by Future Market Insights titled “Outbound Medical Tourism Services Market: North America Industry Analysis and Opportunity Assessment, 2016–2026”, the North America outbound medical tourism services market is expected to reach a market valuation of US$ 15.53 Bn by 2016 end and this is likely to increase to US$ 150.36 Bn by 2026. According to Future Market Insights, factors such as a large ageing baby boomer population, large uninsured population, and better technology and wider treatment options are expected to drive the revenue growth of the North America outbound medical tourism services market over the forecast period. Economic factors such as rising rate of health insurance premiums, high cost of medical treatments in the U.S., and parallel tourism with medical treatment are expected to boost the growth of the North America outbound medical tourism services market between 2016 and 2026. The other factors impacting the North America outbound medical tourism services market are long waiting time for specialist appointments in the U.S. and increasing preference for non-conventional treatment options. The demand for cosmetic correction procedures and dental treatments has been significantly high in the U.S. market in recent years, making North America the most lucrative regional market for outbound medical tourism services. According to the International Society of Aesthetic Plastic Surgery, the U.S. was the largest market for cosmetic procedures in 2015. Lack of effective follow-up care on returning home, rampant medical malpractices in medical tourism destinations, proliferation of superbugs in medical tourism destinations, problems associated with language barriers, and privacy concerns are some of the challenges anticipated to restrict revenue growth of the North America outbound medical tourism services market over the forecast period. The North America outbound medical tourism services market is segmented into the following therapeutic applications – Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment, and Other General Treatment. The Cosmetic Surgery Treatment segment is estimated to be valued at US$ 3,760.9 Mn by 2016 end Preview on North America Outbound Medical Tourism Services Market Segmentation By Therapeutic Application - Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment and Other General Treatment: http://www.futuremarketinsights.com/reports/north-america-outbound-medical-tourism-services-market The Cancer Treatment segment is anticipated to register a CAGR of 22.0% over the forecast period The Orthopaedic Treatment segment is estimated to create absolute $ opportunity of US$ 1,658.9 Mn in 2017 over 2016 The North America outbound medical tourism services market is segmented into the two top countries of U.S and Canada. U.S. is projected to occupy a major share in the North America outbound medical tourism services market in terms of value. The U.S market is anticipated to be valued at US$ 14.98 Bn by the end of 2016. In terms of value, U.S. is expected to be the dominant regional market by 2026 end and is expected to register a CAGR of 25.7% over the forecast period. Canada is expected to have comparatively less market potential for outbound medical tourism services, registering a CAGR of 18.1% over the forecast period. The report profiles some of the top companies operating in the North America outbound medical tourism services market. Leading market players featured in the report are Apollo Hospital Enterprise Limited, Bumrungrad International Hospital, KPJ Healthcare Berhad, Christus Muguerza Hospital, WorldMed Assist, Mednamaste, and Global Medical Tourism Inc. Major market players are adopting strategies such as market expansion and strategic alliances to maintain their market share. Some of these companies are also adopting strategies such as backward integration to support their core business of medical tourism. Companies are offering services such as insurance and financing for medical tourism and are looking to expand their global footprint by enhancing their foreign customer base. For more information, please visit http://www.futuremarketinsights.com/reports/north-america-outbound-medical-tourism-services-market


News Article | November 22, 2016
Site: www.prnewswire.co.uk

According to a new report published by Future Market Insights titled "Outbound Medical Tourism Services Market: North America Industry Analysis and Opportunity Assessment, 2016-2026", the North America outbound medical tourism services market is expected to reach a market valuation of US$ 15.53 Bn by 2016 end and this is likely to increase to US$ 150.36 Bn by 2026. According to Future Market Insights, factors such as a large ageing baby boomer population, large uninsured population, and better technology and wider treatment options are expected to drive the revenue growth of the North America outbound medical tourism services market over the forecast period. Economic factors such as rising rate of health insurance premiums, high cost of medical treatments in the U.S., and parallel tourism with medical treatment are expected to boost the growth of the North America outbound medical tourism services market between 2016 and 2026. The other factors impacting the North America outbound medical tourism services market are long waiting time for specialist appointments in the U.S. and increasing preference for non-conventional treatment options. The demand for cosmetic correction procedures and dental treatments has been significantly high in the U.S. market in recent years, making North America the most lucrative regional market for outbound medical tourism services. According to the International Society of Aesthetic Plastic Surgery, the U.S. was the largest market for cosmetic procedures in 2015. Lack of effective follow-up care on returning home, rampant medical malpractices in medical tourism destinations, proliferation of superbugs in medical tourism destinations, problems associated with language barriers, and privacy concerns are some of the challenges anticipated to restrict revenue growth of the North America outbound medical tourism services market over the forecast period. The North America outbound medical tourism services market is segmented into the following therapeutic applications - Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment, and Other General Treatment. Preview Analysis on North America Outbound Medical Tourism Services Market Segmentation By Therapeutic Application - Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment and Other General Treatment: http://www.futuremarketinsights.com/reports/north-america-outbound-medical-tourism-services-market The North America outbound medical tourism services market is segmented into the two top countries of U.S and Canada. U.S. is projected to occupy a major share in the North America outbound medical tourism services market in terms of value. The U.S market is anticipated to be valued at US$ 14.98 Bn by the end of 2016. In terms of value, U.S. is expected to be the dominant regional market by 2026 end and is expected to register a CAGR of 25.7% over the forecast period. Canada is expected to have comparatively less market potential for outbound medical tourism services, registering a CAGR of 18.1% over the forecast period. Speak with Analyst for any Report Related Queries: http://www.futuremarketinsights.com/askus/rep-na-2158 The report profiles some of the top companies operating in the North America outbound medical tourism services market. Leading market players featured in the report are Apollo Hospital Enterprise Limited, Bumrungrad International Hospital, KPJ Healthcare Berhad, Christus Muguerza Hospital, WorldMed Assist, Mednamaste, and Global Medical Tourism Inc. Major market players are adopting strategies such as market expansion and strategic alliances to maintain their market share. Some of these companies are also adopting strategies such as backward integration to support their core business of medical tourism. Companies are offering services such as insurance and financing for medical tourism and are looking to expand their global footprint by enhancing their foreign customer base. Note to Members of Press: Analysts who have compiled this report are available for interviews and quotes at press@futuremarketinsights.com Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.


Krishnamurthy V.T.,Apollo Hospital
Journal of Cardiovascular Disease Research | Year: 2016

Coronary perforations are classified as type 1-extra luminal crater, type 2-myocardial or pericardial blushing, and type 3-contrast streaming or cavity spilling. Type 3 coronary perforations are associated with high mortality. Treatment modalities of Type 3 coronary perforations include prolonged balloon inflation, pericardiocentesis for cardiac tamponade, coronary artery bypass surgery, and micro coil embolization. A new technique, widely practised, consists of deploying one or more ready to use covered coronary stents to seal the perforation. This has reduced the need for emergency Coronary artery bypass surgery. The author describes here a case of coronary perforation Type 3 occurring unexpectedly after deploying a drug eluting stent across a simple mid left anterior descending artery lesion combined with a situation of non-availability of ready-to-use covered coronary stent in the catheterisation laboratory. A innovative technique of making by hand a covered coronary stent using readily available coronary balloon to cover an appropriately sized coronary stent is described. This handmade covered stent was deployed to seal the coronary perforation successfully and was life saving.


Dash S.K.,Apollo Hospital
Recent Patents on CNS Drug Discovery | Year: 2011

Alzheimer's disease is the most common form of dementia. Alzheimer's disease will be responsible for an enormous burden on the individual and the society, as with the aging of the population, the incidence and the prevalence will grow. Presently, the drugs used in Alzheimer's disease are only effective symptomatically and improve functioning. They do not halt the progression of the disease. With the recent advances in our understanding of the pathogenesis of this disease, there have been tremendous advances in the clinical trials of compounds that can modify the disease process. Numerous therapeutic interventions and neuroprotective approaches are also in trial phase. It seems that in near future some of these compounds may be found effective and safe for use in this disease there by reducing the incidence of this disease in years to come, thereby lessen the burden due to it. In this article various compounds that can modify the course of the disease are discussed. Some recent patents and inventions for the treatment of Alzheimer's disease have also been discussed. © 2011 Bentham Science Publishers Ltd.


Prasad A.,Apollo Hospital
World Journal of Gastroenterology | Year: 2010

As a complement to standard laparoscopic surgery and a safe alternative to natural orifice transluminal endoscopic surgery, single incision laparoscopic surgery is gaining popularity. There are expensive ports, disposable hand instruments and flexible endoscopes that have been suggested to do this surgery and would increase the cost of operation. For a simple surgery like laparoscopic cholecystectomy, these extras are not needed and the surgery can be performed using standard ports, instruments and telescopes. Triangular port insertion and use of instruments by the "chop stick method" are recommended to successfully do the procedure as we have done in our so far small series of 40 cases. © 2010 Baishideng. All rights reserved.


Krishnamurthy V.T.,Apollo Hospital
Journal of Cardiovascular Disease Research | Year: 2016

Hemophilia B with acute myocardial infarction is rare and presents a management challenge. Acute myocardial infarction demands restoration of blood flow to the jeopardised myocardium at the earliest. With a background of easy tendency to a major bleed in Hemophilia B, use of fibrinolytic therapy, antiplatelets, or anticoagulants are fraught with danger. A 52 year male with Hemophilia B, on regular maintainance doses of factor IX replacement, presented with acute anterior wall myocardial infarction. Patient had a history of oral bleed the previous day. His further management presented a challenge as fibrinolytic therapy or primary percutaneous intervention with stenting and subsequent use of antiplatelets and anticoagulants would invite the danger of life threatening major bleed. Patient had primary percutaneous coronary intervention under cover of one antiplatelet therapy and plain balloon angioplasty to culprit vessel was carried out with good outcomes.


Dysfunctional voiding (DV) is a voiding disorder characterized by dyssynergic striated sphincteric activity in the absence of a proven neurological etiology. It can present at any age with a spectrum of storage and voiding symptoms that may resemble florid neurogenic bladder. There is a striking lack of clarity regarding what this entity represents, the diagnostic methodology and treatment. The limitations of existing guideline documents are analyzed. Specifically, use of the term "habitual", the assumption that bladder changes are secondary to the outlet, the emphasis on "staccato" voiding and the implication of striated urethral sphincter are discussed. Literature shows that DV may also present with continuous slow flow or normal flow. Dyssynergia may be at the level of the striated urethral sphincter, the pelvic floor or both, better termed "striated urethral sphincter-pelvic floor complex" (SUS-PFC).A diagnostic algorithm is provided so that patients are evaluated on merit rather than on the basis of different philosophies of individual centers. High-risk markers such as hydronephrosis, vesicoureteral reflux, renal failure or marked voiding difficulty should prompt a formal urodynamics evaluation and imaging for neurological etiology. Patients with predominantly storage symptoms with incidental staccato voiding can be managed initially, on the basis of non-invasive evaluation. Conservative urotherapy including biofeedback is appropriate initial management for patients without high risk factors. Treatment and evaluation should be escalated based on response. Patients with severe DV will need treatment similar to neurogenic bladder including clean intermittent catheterization and measures to control storage pressures.


Mani M.K.,Apollo Hospital
Seminars in Nephrology | Year: 2010

The treatment of renal disease is expensive, and only a few Indians can afford it. The vast majority of Indians are poor. Nephrologists and facilities for treating renal disease are found only in larger cities. The renal unit of Apollo Hospital uses the new communications network of the country to guide patients with chronic kidney disease in increasing the dose of angiotensin converting enzyme inhibition to the maximum and thereby slow down the decline of renal function. The rate of decline of estimated glomerular filtration rate in diabetic nephropathy has decreased from 16 mL/min/y in 1993 to 2.7 mL/min/y in 2008, and in chronic glomerulonephritis from 28 to 2.8, respectively. In the entire group of patients with renal failure of all causes, the projected increase in time to reach the end stage from a glomerular filtration rate of 50 mL/min is 26 years, which is 17 years longer than the controls. Because hardly any of these patients can afford dialysis or transplantation, this is indeed an extra lease of life. © 2010.

Loading Apollo Hospital collaborators
Loading Apollo Hospital collaborators